£41.7M
The Series A round will fund the continued development of the company platform for hard-to-drug targets.
CHARM Therapeutics
Discovering small molecule therapeutics through proprietary 3D deep-learning protein-ligand technology.
£41.7MTotal raised
CHARM Therapeutics applies 3D deep-learning protein-ligand co-folding technology to develop small molecule therapeutics against challenging targets in cancer and other areas. The London-based company uses its proprietary DragonFold platform to pioneer structure-based drug design.
Categories
Founders
LA
Laksh Aithani
Chief Executive Officer
DB
David Baker
Head of the Institute for Protein Design, University of Washington